Guardant Health Inc (GH) Stock Price & News

Q3 2026 earnings • released • EPS beat +7,77% • Revenue beat +2,95%

See results

GH:NASDAQ

Guardant Health Inc

USD 153,43

-8,99%

(-15,15) 1D

USD 143,00

-6,80% (-10,43)

Pre-market

Closed: 5 Nov., 16:00:02 GMT-5 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for GH...

Open

USD 165,00

High

USD 165,10

Low

USD 151,92

Mkt. cap

20,59 mjd

Avg. vol.

1,81 m

Volume

5,52 k

52-wk high

USD 191,01

52-wk low

USD 74,55

EPS

-USD 3,50

Beta

1,67

Shares outstanding

134,20 m

No. of employees

2 k

Open

USD 165,00

High

USD 165,10

Low

USD 151,92

Mkt. cap

20,59 mjd

Avg. vol.

1,81 m

Volume

5,52 k

52-wk high

USD 191,01

52-wk low

USD 74,55

EPS

-USD 3,50

Beta

1,67

Shares outstanding

134,20 m

No. of employees

2 k

Related stocks

Twist Bioscience Corp

USD 120,61

-15,41%

News stories

From web sources and news partners

Investing.com

1 uur gelede

Guardant Health stock reiterated at Buy by BTIG after Q3 beat

GenomeWeb

10 uur gelede

Guardant Health Q3 Revenue Climbs 36 Percent as Firm Raises Full-Year Guidance

Zacks

11 uur gelede

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

Securities.io

11 uur gelede

Guardant Health Lifts 2026 Revenue Outlook as Screening Surges

Profile

Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia

About Guardant Health Inc

CEOHelmy Eltoukhy | AmirAli Talasaz

Employees2,5 k

Founded2012

HeadquartersPalo Alto, Kalifornië, Verenigde State van Amerika

SectorHealth Care

IndustryHealth care provider

Websiteguardanthealth.com

Analyst ratings

Based on 14 analysts giving stock ratings to GH in the past 3 months

Strong buy

Buy

Hold

Sell

12-month forecast

Based on 14 Wall Street analysts offering 12 month price targets for GH in the last 3 months.

Highest

Current USD 153,43

USD 225,00 (+46,65%)

Average

USD 206,75 (+34,75%)

Lowest

USD 193,00 (+25,79%)

Analyst	Recommendation	Action	Price target	Projected	Date
Luke Sergott Barclays	Buy	Maintained	USD 220,00	+43,4%	11/06/2026
Mark Massaro BTIG	Buy	Maintained	USD 210,00	+36,9%	10/27/2026
Max Masucci Roth MKM	Buy	Initiated	USD 200,00	+30,4%	10/22/2026
Kallum Titchmarsh Morgan Stanley	Buy	Maintained	USD 200,00	+30,4%	10/20/2026
Eve Burstein Bernstein	Buy	Reiterated	USD 210,00	+36,9%	10/19/2026
Casey Woodring J.P. Morgan	Buy	Maintained	USD 195,00	+27,1%	10/14/2026
Lu Li Bank of America Securities	Buy	Maintained	USD 200,00	+30,4%	10/09/2026
Michael Ryskin Bank of America Securities	Buy	Maintained	USD 200,00	+30,4%	10/09/2026
Subbu Nambi Guggenheim	Buy	Maintained	USD 200,00	+30,4%	10/01/2026
Evie Koslosky Goldman Sachs	Buy	Maintained	USD 225,00	+46,6%	09/20/2026
William Bonello Craig-Hallum	Buy	Maintained	-	-	09/15/2026
David Westenberg Piper Sandler	Buy	Maintained	USD 193,00	+25,8%	09/15/2026
Unknown Analyst UBS	Buy	Maintained	USD 225,00	+46,6%	09/09/2026
Doug Schenkel UBS	Buy	Maintained	USD 225,00	+46,6%	09/09/2026
Jamie Clark Rothschild & Co Redburn	Buy	Initiated	USD 203,00	+32,3%	09/08/2026
Matt Larew William Blair	Buy	Maintained	-	-	09/08/2026
Bradley Bowers Mizuho Securities	Buy	Maintained	USD 200,00	+30,4%	08/04/2026
Mason Carrico Stephens	Buy	Maintained	USD 195,00	+27,1%	08/04/2026
Kyle Mikson CFA Canaccord Genuity	Buy	Maintained	USD 205,00	+33,6%	08/02/2026
Daniel Arias Stifel Nicolaus	Buy	Maintained	USD 180,00	+17,3%	08/03/2026
Dan Leonard RBC Capital	Buy	Reiterated	USD 200,00	+30,4%	07/31/2026
Daniel Brennan TD Cowen	Buy	Reiterated	USD 210,00	+36,9%	07/31/2026
Brandon Couillard Wells Fargo	Buy	Maintained	USD 125,00	-18,5%	07/29/2026
Patrick B Donnelly Citi	Buy	Maintained	USD 215,00	+40,1%	07/08/2026
Vijay Kumar Evercore ISI	Buy	Maintained	USD 200,00	+30,4%	07/06/2026
Puneet Souda Leerink Partners	Buy	Reiterated	-	-	06/02/2026
Paige Chamberlain‏ Wolfe Research	Buy	Reiterated	USD 150,00	-2,2%	06/01/2026
Unknown Analyst Wolfe Research	Buy	Reiterated	USD 150,00	-2,2%	06/01/2026
Andrew Brackmann William Blair	Buy	Maintained	-	-	05/27/2026
Catherine Ramsey Schulte Robert W. Baird	Buy	Maintained	USD 129,00	-15,9%	05/08/2026
Andrew Cooper Raymond James	Buy	Reiterated	USD 129,00	-15,9%	02/23/2026

All values in USD	Sep. 2025	Des. 2025	Mrt. 2026	Jun. 2026
Revenue	265,20 m	281,27 m	301,66 m	334,98 m
Cost of goods sold	93,59 m	99,49 m	104,92 m	115,95 m
Cost of revenue	93,59 m	99,49 m	104,92 m	115,95 m
Research and development expenses	89,96 m	98,26 m	91,04 m	96,53 m
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	180,53 m	204,20 m	227,06 m	250,61 m
Operating expense	270,48 m	302,46 m	318,10 m	347,15 m
Total operating expenses	364,07 m	401,96 m	423,02 m	463,10 m
Operating income	-98,87 m	-120,69 m	-121,35 m	-128,12 m
Other non operating income	-48,00 k	-4,69 m	1,55 m	308,00 k
EBT including unusual items	-92,59 m	-130,22 m	-111,70 m	-119,96 m
EBT excluding unusual items	-92,47 m	-116,52 m	-111,70 m	-118,96 m
Income tax expense	136,00 k	-1,73 m	372,00 k	185,00 k
Effective tax rate	-0,15%	1,33%	-0,33%	-0,15%
Other operating expenses	-	-	-	-
Net income	-92,72 m	-128,49 m	-112,08 m	-120,14 m
Net profit margin	-34,96%	-45,68%	-37,15%	-35,87%
Earnings per share	-0,39	-0,50	-0,45	-0,42
Interest and investment income	7,39 m	10,03 m	11,15 m	10,20 m
Interest expense	-943,00 k	-1,18 m	-3,05 m	-1,35 m
Net interest expenses	6,45 m	8,85 m	8,10 m	8,85 m
Depreciation and amortization charges	-	-	-	-
EBITDA	-89,47 m	-110,64 m	-111,91 m	-118,56 m
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything